# Opko Health Inc. (OPK)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.08B  
**Price:** $1.44

> OpKO Health Inc. is a multinational biopharmaceutical and diagnostics company operating through two primary segments: Pharmaceuticals and Diagnostics. In the Pharmaceuticals segment, it develops and commercializes therapies such as Rayaldee, FDA-approved for treating secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency, and Somatrogon (hGH-CTP), approved in over 50 markets for growth hormone deficiency in children and adolescents. The company advances multispecific therapies targeting cancers and infectious diseases, partnering with leading pharmaceutical firms to deliver next-generation solutions for serious conditions across global markets. Its Diagnostics segment, primarily through BioReference Health, LLC, provides comprehensive clinical laboratory testing services, including the 4Kscore prostate cancer test, serving physicians, hospitals, clinics, and healthcare facilities nationwide with a network of labs. Founded in 1991 and headquartered in Miami, Florida, OpKO Health Inc. focuses on improving patient outcomes in healthcare and biopharmaceutical sectors.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $607M | $206M | -$117M | -$226M | — |
| 2024 | $713M | $219M | -$152M | -$53M | — |
| 2023 | $863M | $318M | -$157M | -$189M | — |
| 2022 | $1.00B | $288M | -$226M | -$328M | — |
| 2021 | $1.77B | — | $19M | -$30M | — |
| 2020 | $1.44B | — | $58M | $31M | — |
| 2019 | $902M | — | -$274M | -$315M | — |
| 2018 | $990M | — | -$171M | -$153M | — |
| 2017 | $966M | $905M | -$276M | -$305M | — |
| 2016 | $1.12B | $553M | -$97M | -$48M | — |
| 2015 | $492M | $298M | -$98M | -$30M | — |
| 2014 | $91M | $82M | -$146M | -$172M | — |
| 2013 | $97M | $86M | -$80M | -$114M | — |
| 2012 | $47M | $19M | -$37M | -$29M | — |
| 2011 | $28M | $11M | -$23M | -$1M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.93B | $664M | $1.27B | $364M | $344M |
| 2024 | $2.20B | $835M | $1.37B | $427M | $437M |
| 2023 | $2.01B | $622M | $1.39B | $96M | $50,600 |
| 2022 | $2.17B | $606M | $1.56B | $153M | $256M |
| 2021 | $2.40B | $715M | $1.69B | $135M | $205M |
| 2020 | $2.47B | $802M | $1.67B | $72M | $251M |
| 2019 | $2.31B | $695M | $1.61B | $85M | $270M |
| 2018 | $2.45B | $660M | $1.79B | $96M | $5M |
| 2017 | $2.59B | $746M | $1.84B | $91M | $2M |
| 2016 | $2.77B | $675M | $2.05B | $169M | $717,000 |
| 2015 | $2.80B | $819M | $2.00B | $194M | $3M |
| 2014 | $1.27B | $432M | $842M | $97M | $2M |
| 2013 | $1.39B | $519M | $876M | $186M | $3M |
| 2012 | $290M | $87M | $179M | $27M | $5M |
| 2011 | $229M | $44M | $161M | $72M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$179M | — | — |
| 2024 | -$183M | — | — |
| 2023 | -$28M | — | — |
| 2022 | -$95M | — | — |
| 2021 | $38M | — | — |
| 2020 | $39M | — | — |
| 2019 | -$173M | — | — |
| 2018 | -$109M | — | — |
| 2017 | -$92M | — | — |
| 2016 | $32M | — | — |
| 2015 | $164M | — | — |
| 2014 | -$90M | — | — |
| 2013 | -$56M | — | — |
| 2012 | -$25M | — | — |
| 2011 | -$19M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/OPK)